FDA releases final guidance on tobacco product research

Aug.24.2022
FDA releases final guidance on tobacco product research
FDA releases final guide to help applicants design and conduct tobacco product intention studies.

On August 23rd, the U.S. Food and Drug Administration (FDA) released its final guidelines on guiding research into tobacco product intentions (TPPI).


Tobacco Products: Principles for Design and Implementation of Tobacco Product Intention Studies" is aimed at assisting applicants in completing studies related to the design and risk assessment of Modified Risk Tobacco Products (MRTP), Tobacco Product Marketing Applications (PMTA) including TPPI studies, or Equivalent Reports (SE) before their release to the market.


The FDA has stated that TPPI research can be used to assess individuals' views on tobacco products, understanding of tobacco product information (such as labeling and modified risk information), and intentions to use tobacco products. These studies provide crucial information during product application reviews, and this guide offers recommendations on how to conduct such research.


The Final Guidance addresses several scientific issues that applicants need to consider when designing and conducting studies on Tobacco Product Pathways of Introduction (TPPI) to support the application of tobacco products.


Developing research objectives and hypotheses, designing quantitative and qualitative research, selecting and adjusting measures of learning structure, determining research outcomes, selecting and proving research samples, and analyzing research results.


The FDA has announced that the purpose of this guidance document is to provide clarity on existing regulatory requirements for applicants. According to the agency's statement, "FDA guidance documents, including this one, should be considered as recommendations for consideration, unless specific regulatory or statutory requirements are referenced.


Announcement


This article is compiled from third-party information and is intended for industry communication and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is solely intended for industry-related communication and research purposes.


Due to the limitations of the translation skills, the translated article may not fully express the same meaning as the original. Therefore, please refer to the original article for accuracy.


2FIRSTS maintains full alignment with the Chinese government's position regarding any domestic, Hong Kong, Macao, Taiwan, or foreign-related statements and stances.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
During the FDA PMTA roundtable session on “Studies of Adult Benefit,” officials said flavored ENDS must demonstrate “added benefit” over tobacco-flavored products under the APPH standard, including sustained complete switching evidence. Small manufacturers questioned switching benchmarks, study duration, and bridging expectations.
Feb.11
Product | Vaporesso lists Vibe SE 2 on official site, offering leather/plated versions and a 1,400mAh battery
Product | Vaporesso lists Vibe SE 2 on official site, offering leather/plated versions and a 1,400mAh battery
Vaporesso has recently listed the Vibe SE 2, a new device in its Vibe series, on the brand’s official website. The product is positioned as an entry-level MTL device and features a 1,400mAh built-in battery with Type-C 1A charging. It is available in two finishes—Leather and Plated—while listings on online retail channels show prices of around $17.99 and £22.99.
Jan.30 by 2FIRSTS.ai
Finnish Customs Investigate Firm Suspected of Importing and Selling Nicotine Pouches Without Paying Tobacco Tax
Finnish Customs Investigate Firm Suspected of Importing and Selling Nicotine Pouches Without Paying Tobacco Tax
Finnish Customs are investigating a firm suspected of importing and selling nicotine pouches without paying tobacco tax. Two Finnish citizens have been questioned as part of the probe. The authority believes the nicotine pouches were imported into Finland from other EU countries before being distributed to Finnish retailers.
Mar.11 by 2FIRSTS.ai
New York Nicotine Pouch Tax Moves Forward as Critics Question Public Health Impact
New York Nicotine Pouch Tax Moves Forward as Critics Question Public Health Impact
New York Governor Kathy Hochul included in her FY 2027 budget proposal a plan to impose the same 75% wholesale tax on nicotine pouches such as Zyn that applies to cigarettes. The measure is expected to raise USD 18 million in FY 2027 and USD 44 million in FY 2028 after full implementation.
Mar.30 by 2FIRSTS.ai
Alaska AG warns 1,500+ retailers to stop selling unauthorized vapes and nicotine pouches
Alaska AG warns 1,500+ retailers to stop selling unauthorized vapes and nicotine pouches
Alaska’s attorney general has sent warning letters to more than 1,500 retailers and distributors, cautioning them against selling tobacco products — including e-cigarettes and oral nicotine pouches — that lack U.S. Food and Drug Administration authorization.
Mar.06 by 2FIRSTS.ai
BAT’s Product Strategy Reset: A Structural Analysis of Its Post-FY2025 Competitive Architecture
BAT’s Product Strategy Reset: A Structural Analysis of Its Post-FY2025 Competitive Architecture
Drawing on BAT’s FY2025 results and earnings call, 2Firsts finds the company shifting from category expansion to competitive entrenchment across Vapour, Modern Oral, Heated Products and Combustibles. The strategy centers on connected devices, geographic customization and portfolio tiering. While structurally coherent, financial returns depend on consistent regulatory enforcement against illicit competitors, making policy execution a key variable for 2026 performance.
Feb.12